Why the study?
Does dobutamine infusion reduce renal sympathetic activity in patients with heart failure?
Does dobutamine infusion reduce renal sympathetic activity in patients with heart failure?
In patients with heart failure, acute dobutamine infusion reduces renal sympathetic activity and improves renal plasma flow and glomerular filtration rate.
Answers are grounded in this paper and cite their sources.
Acute dobutamine was associated with renal sympathetic reduction in HF; hypothesis-generating and requires randomized confirmation before practice change.
The pathophysiology of the cardiorenal syndrome remains poorly understood. Renal sympathetic activity is increased in heart failure. It contributes to the sodium avid state, renal vasoconstriction, and reduced glomerular filtration rate that is characteristic of a large number of heart failure patients. Dobutamine is commonly used in the treatment of decompensated heart failure. We used the norepinephrine spillover technique to examine the effects of dobutamine on renal sympathetic activity in human heart failure. Dobutamine was titrated to increase the peak positive rate of change in left ventricular pressure by 25%. In 11 patients with heart failure, dobutamine infusion reduced efferent renal sympathetic activity by 50% (P < 0.003). This sympatholytic response was associated with an 11% increase in renal plasma flow (P < 0.03) and a 12% increase in glomerular filtration rate (P < 0.04). These findings suggest that dobutamine infusion is acutely associated with a beneficial effect on renal function. This observation is potentially related to a renal sympatholytic response to ventricular mechanoreceptor activation associated with the inotropic effects of beta-adrenergic receptor stimulation.
No takes yet. Share an insight, caveat, or question.
Al‐Hesayen et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: